Journal of Pharmacy Practice and Research最新文献

{"title":"Elective surgery cancellations due to suboptimal medicine management: a retrospective single site study","authors":"Kate Elizabeth Doreen Ziser BPharm, GradDdpEd APP[II], MClinPharm,&nbsp;Jessica Barbara King BPharm,&nbsp;Natasha Alkass BPharm,&nbsp;Jane Elizabeth Dunsdon BPharm, BNursing APP[II]","doi":"10.1002/jppr.1876","DOIUrl":"10.1002/jppr.1876","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Elective surgery cancellations and delays are associated with negative financial and staffing ramifications, adverse clinical outcomes, and poor patient outcomes. The Princess Alexandra Hospital in Brisbane, Australia, performs approximately 15 000 elective surgeries per year and medication optimisation is pivotal in preparing a patient for surgery to avoid same day of surgery theatre cancellations. Ideally, patients are seen in a multidisciplinary pre-admission clinic for optimisation of their health and medicines, and to provide education regarding their surgery.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Aim</h3>\u0000 \u0000 <p>To calculate the incidence of elective surgery cancellations due to medication misadventure over a 12-month period.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Method</h3>\u0000 \u0000 <p>A retrospective audit at a tertiary Queensland Hospital was conducted over a 12-month period (April 2021–March 2022), including patients who had their elective surgeries cancelled. The medical records from the hospital's digital databases for patients who were identified by the hospital coding service as ‘unfit for surgery’ were screened to see if the reason for the surgery cancellation was due to medication misadventure. The project was reviewed by the Metro South Human Research Ethics Committee and deemed exempt from further review (Ref No: CM20221651).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The surgery cancellation rate was 50% (<i>n</i> = 6626 cancelled surgeries from 13 255 total surgeries booked). The same day of surgery cancellation rate was 5.5% (<i>n</i> = 734). Medication misadventure resulting from suboptimal medicine management was responsible for 1% (<i>n</i> = 66 out of 6626 surgery cancellations). A total of 41% (<i>n</i> = 27) of patients had their surgery cancelled ahead of time by the pharmacist due to a medication not being withheld for long enough, which prevented a same-day cancellation.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Having a pre-admission clinic pharmacist improves preoperative medication optimisation and has been proven to avoid same-day cancellations.</p>\u0000 </section>\u0000 </div>","PeriodicalId":16795,"journal":{"name":"Journal of Pharmacy Practice and Research","volume":"53 5","pages":"256-261"},"PeriodicalIF":2.1,"publicationDate":"2023-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44965570","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Standard of practice in mental health for pharmacy services","authors":"Helen Lowy BSc (Hons), PGDipClinPharm, MPhil, PGDipCounselling, FSHP,&nbsp;Viandro Borja BPharm (Hons), GradCertPharmPrac, MClinPharm, MSHP,&nbsp;Stewart Bailey BPharm, DipMgt, MPS, MSHP,&nbsp;Cecilia Bjorksten BPharm, MPS, MSHP, FACP, AACPA,&nbsp;Alice Kochman BPharm, MClinPharm, MSHP,&nbsp;Judy Longworth BPharm, MPharm (Clin), FSHP,&nbsp;Alistair Meldrum BPharm (Hons), MClinPharm, MSHP,&nbsp;Amy Sieff BBiomedSc, MPharm, GradCertLShip (HlthHumServ), MSHP,&nbsp;Lesley Smith BPharm, AdvPP (II), BCPP, MSHP,&nbsp;Alice Wisdom BPharm (Hons), MSHP,&nbsp;Yee Mellor BPharm, MCncrSc, GPhC, MSHP","doi":"10.1002/jppr.1874","DOIUrl":"10.1002/jppr.1874","url":null,"abstract":"Standard of practice in mental health for pharmacy services Helen Lowy, BSc (Hons), PGDipClinPharm, MPhil, PGDipCounselling, FSHP*, Viandro Borja, BPharm (Hons), GradCertPharmPrac, MClinPharm, MSHP, Stewart Bailey, BPharm, DipMgt, MPS, MSHP, Cecilia Bjorksten, BPharm, MPS, MSHP, FACP, AACPA, Alice Kochman, BPharm, MClinPharm, MSHP, Judy Longworth, BPharm, MPharm (Clin), FSHP, Alistair Meldrum, BPharm (Hons), MClinPharm, MSHP, Amy Sieff, BBiomedSc, MPharm, GradCertLShip (HlthHumServ), MSHP, Lesley Smith, BPharm, AdvPP (II), BCPP, MSHP, Alice Wisdom, BPharm (Hons), MSHP, Yee Mellor, BPharm, MCncrSc, GPhC, MSHP 1 Mental Health Leadership Committee, The Society of Hospital Pharmacists of Australia, Abbotsford, Victoria, Australia 2 Helen Lowy Counselling and Psychotherapy, Frankston South, Victoria, Australia 3 Pharmacy Department, Alfred Health, Melbourne, Victoria, Australia 4 Faculty of Pharmacy and Pharmaceutical Science, Monash University, Parkville, Victoria, Australia 5 Pharmacy Department, Darling Downs Health, Toowoomba, Queensland, Australia 6 Hunter New England Mental Health Service, Waratah, New South Wales, Australia 7 Pharmacy Department, Austin Health, Heidelberg, Victoria, Australia 8 The Children’s Hospital at Westmead, Sydney Children’s Hospital Network, Sydney, NSW, Australia 9 Rockhampton Hospital Pharmacy Department, Central Queensland Hospital and Health Service, Rockhampton, Queensland, Australia 10 South Western Sydney Local Health District, Warwick Farm, New South Wales, Australia 11 Pharmacy Department, Princess Alexandra Hospital, Woolloongabba, Queensland, Australia 12 SA Pharmacy, SA Health, Adelaide, South Australia, Australia 13 The Society of Hospital Pharmacists of Australia, Abbotsford, Victoria, Australia","PeriodicalId":16795,"journal":{"name":"Journal of Pharmacy Practice and Research","volume":"53 4","pages":"204-225"},"PeriodicalIF":2.1,"publicationDate":"2023-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43683921","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A review of pharmacy-led interventions: identification of facilitators and barriers for the design of a new model of care for asthma","authors":"Neera Rajballi-Naidoo BSC.Pharm, PGDipHS, MHSc,&nbsp;Kyle John Wilby PharmD, PhD,&nbsp;Amber Young BPharm, PGCertPharm, PGCertGPP, PhD,&nbsp;Alesha Smith BSc, MSc, PhD, MBA","doi":"10.1002/jppr.1870","DOIUrl":"10.1002/jppr.1870","url":null,"abstract":"<p>The objective of this narrative review was to determine the facilitators and barriers identified in pharmacy-led interventions that improve outcomes in patients with asthma and support the implementation of interventions in practice. EMBASE, Web of Science, Google Scholar, and PubMed were used to identify 17 relevant articles. Seven studies were randomised controlled studies and 10 were one-arm, pre-post evaluations of all participants enrolled. Questionnaires assessing asthma control, medicine adherence, and knowledge about asthma were used, while checklists were used to assess inhaler technique. Studies with planned interventions in a clinic or general practice setting and lasting for 6 months (compared to longer interventions of 48 weeks) were more successful in retaining participation in the program. Education was the key intervention in which inhaler technique training was the most common. Knowledge about the disease, its aetiology, trigger factors, and medication used were covered in 10 of the studies. Fifteen of the articles reported an improvement in the asthma of patients receiving intervention by the pharmacist, measured by their asthma control test scores, emergency department visits, or reduced emergency steroid prescriptions. This review highlights five key requirements for the success of pharmacy-based interventions for asthma management: (a) developing and maintaining a skilled workforce; (b) close proximation of a general practitioner practice or clinic to the pharmacy; (c) patient education on the disease and medicine; (d) structured and standardised intervention and assessment; and (e) length of the intervention suitable to the pharmacist and the patient.</p>","PeriodicalId":16795,"journal":{"name":"Journal of Pharmacy Practice and Research","volume":"53 5","pages":"227-240"},"PeriodicalIF":2.1,"publicationDate":"2023-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jppr.1870","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45639474","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pharmacist ambulatory pain services for a chronic non-cancer pain clinic: a descriptive study","authors":"Sam Maleki BPharm, MPharmPrac,&nbsp;Jeremy Szmerling BPharm,&nbsp;Mahisha Thiruvasagan BPharm, MPharmPrac,&nbsp;Gloria Seah FFPMANZCA, FANZCA, MMed(Periop), MBBS,&nbsp;Galahad Gu BPharm(Hons), MPharmPrac","doi":"10.1002/jppr.1875","DOIUrl":"10.1002/jppr.1875","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Patients presenting to specialist pain clinics are often prescribed complex and high-risk analgesic regimens. In this setting, pharmacists can help identify at risk patients and provide valuable clinical input to improve patient outcomes.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Aim</h3>\u0000 \u0000 <p>To evaluate the role of a clinical pharmacist in improving the triage, assessment and management of patients presenting to ambulatory pain clinics.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Method</h3>\u0000 \u0000 <p>This descriptive study enrolled patients from two chronic noncancer pain clinics from July to December 2021. A new clinical pharmacist service was devised, which operated as telehealth one day per week. The pharmacist was responsible for accepting referrals, triaging based on clinic criteria and updating them with prescription risk factors, in line with SafeScript's traffic light system. Pharmacist clinical services included completion of medication histories, drug dose interventions and patient education. This project received departmental ethical approval from the Eastern Health Office of Research and Ethics prior to commencement (Approval No: QA21-068).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The pharmacist assessed 253 patients and identified prescription risk factors for 68 patients; of which 11 (16%) had received opioids from ≥4 prescribers, 10 (15%) were issued a monitored prescription from ≥4 pharmacies, seven (10%) were on high-risk drug combinations, 25 (37%) had an Oral Morphine Equivalent Daily Dose (OMEDD) of 50–100 mg, and 26 (38%) with OMEDD &gt;100 mg. The pharmacist completed 67 medication histories and provided 22 accepted drug intervention recommendations to clinic physicians, including seven recommendations for dose adjustments, six to cease a medicine and nine to start a new medicine.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>The pharmacist incorporated SafeScript in the clinics' triage processes and provided valuable clinical interventions complementing the care provided by the pain physicians and the allied health staff.</p>\u0000 </section>\u0000 </div>","PeriodicalId":16795,"journal":{"name":"Journal of Pharmacy Practice and Research","volume":"53 5","pages":"241-247"},"PeriodicalIF":2.1,"publicationDate":"2023-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42258986","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Forgotten but not gone: calcium-alkali syndrome","authors":"Shrey Seth Pharm D,&nbsp;Lukas Kairatis MBBS, FRACP, PhD,&nbsp;Ronald L. Castelino BPharm, MPharm, PhD","doi":"10.1002/jppr.1873","DOIUrl":"10.1002/jppr.1873","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Calcium-alkali syndrome (CAS) is characterised by hypercalcaemia, metabolic alkalosis, and renal injury. CAS has been a long-standing concern but has fallen off the radar in recent times. However, supplementation of calcium and vitamin D for osteoporosis, and use of calcium based antacids for reflux has led to its resurgence as one of the leading causes for hypercalcaemia-induced hospitalisations.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Aim</h3>\u0000 \u0000 <p>We present a case of CAS owing to excessive consumption of calcium carbonate in the presence of vitamin D.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Clinical details</h3>\u0000 \u0000 <p>An 84-year-old woman presented to the hospital emergency room for the second time in 4 months after CAS was missed during the first admission. A history of significant (6–8 tablets daily) Quick-Eze use (calcium carbonate), Gaviscon dual action antacid (calcium carbonate 32.5 mg/mL, sodium bicarbonate 21.3 mg/mL, sodium alginate 50 mg/mL) for reflux, and 2000 IU of vitamin D capsules for osteoporosis was the likely reason for CAS. COVID-19 lockdown and the inability to fill esomeprazole scripts had increased the patient's reliance on over-the-counter treatments for reflux.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Outcomes</h3>\u0000 \u0000 <p>The severe hypercalcaemia was treated using intravenous fluids and pamidronate, following which her serum calcium levels normalised, with resolution of symptoms.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>The effect of Quick-Eze tablets on the development of hypercalcaemia should not be underestimated, especially in the presence of interacting medicines or supplements. This report highlights the importance of accurate history taking as the hypercalcaemia was missed during the patient's initial visit. Appropriate warning labels are warranted on Quick-Eze tablets, as the current information is ambiguous, with no specific information on duration.</p>\u0000 </section>\u0000 </div>","PeriodicalId":16795,"journal":{"name":"Journal of Pharmacy Practice and Research","volume":"53 5","pages":"268-270"},"PeriodicalIF":2.1,"publicationDate":"2023-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jppr.1873","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45738278","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Design and implementation of an electronic opioid management plan to support consistent communication of opioid analgesia prescribing intentions to patients and general practitioners","authors":"Elizabeth Su BPharm(Hons), GradCertPharmPrac, MPharmPrac, CHIA,&nbsp;Parnaz Aminian BPharm(Hons), GradCertPharmPrac,&nbsp;Christopher McMaster MBBS, BSc/BA, GradDipBiostats, CHIA, FRACP,&nbsp;Jade Eyles BPharm(Hons), MPharmPrac,&nbsp;Albert G. Frauman MBBS, MD, FRACP, FACCP, FACP,&nbsp;Kent Garrett BPharm, GradDipHospPharm,&nbsp;Simone E. Taylor BPharm, PharmD, GradCertClinResMeth,&nbsp;David F. L. Liew MBBS, FRACP, CHIA","doi":"10.1002/jppr.1872","DOIUrl":"10.1002/jppr.1872","url":null,"abstract":"<p>Opioid prescribing requires careful planning to minimise the risk of serious adverse outcomes. However, documentation of discharge opioid plans for patients and their general practitioners (GPs) is inconsistent, particularly when opioids are commenced in the emergency department or after surgery. We describe an initiative to promote consistent discharge opioid plan communication by implementing an opioid management plan (OMP) in our hospital's electronic medical record. Completion of an electronic form by the prescriber generates an OMP note in the medical history, which is used by the pharmacist to provide tailored opioid patient education. The OMP also populates the discharge summary that is sent to the GP and the Australian national digital health record platform, My Health Record. Preliminary evaluation shows incorporating OMP documentation into routine workflows has assisted prescribers to consistently document the plan for supplied opioids, supporting continuity of care. Workflow optimisation is ongoing to further improve discharge summary documentation and provision of patient-friendly written information. This study was conducted as a quality improvement project and audits conducted as part of the project were approved by Austin Health's Office for Research (Project No: LNR/18/Austin/155). Informed patient consent was not required by Austin Health.</p>","PeriodicalId":16795,"journal":{"name":"Journal of Pharmacy Practice and Research","volume":"53 4","pages":"186-194"},"PeriodicalIF":2.1,"publicationDate":"2023-06-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48830165","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluating the patient-perceived impact of a neratinib special access program in an Australian community pharmacy","authors":"Jessie Zhang,&nbsp;Lynn Cheong BPharm, PhD","doi":"10.1002/jppr.1871","DOIUrl":"10.1002/jppr.1871","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>In Australia, breast cancer is the most commonly diagnosed cancer in women, and improved survival rates have placed an increased burden on the healthcare system. To better utilise community pharmacists in anticancer therapy, a medicine management service for neratinib was initiated in an Australian community pharmacy for patients with breast cancer.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Aim</h3>\u0000 \u0000 <p>To explore the experience and satisfaction of Australian breast cancer patients who received a pharmacist medicine management service for their neratinib treatment through a community pharmacy.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Method</h3>\u0000 \u0000 <p>Patients enrolled in the neratinib special access program were invited to complete an electronic survey between February–September 2019. A mixed-methods approach was utilised in data analysis. Ethics approval was granted by the University of Canberra Human Research Ethics Committee (Project No: 20181648).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Thirty-three individuals completed the survey. A majority of participants (94%) were either ‘very satisfied’ or ‘satisfied’ with the time the pharmacist spent with them. As part of the service, 88% of participants viewed the first pharmacist session as ‘absolutely’ worthwhile and 79% believed that the pharmacist interaction increased their understanding of neratinib therapy. Many participants supported the continued provision and expansion of the service (88%).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>This pilot study provided valuable insights into participants' experiences of a pharmacist medicine management service for neratinib therapy. The unique preferences and health information needs of patients were highlighted. Further investigation is needed to explore how community pharmacists may be best utilised to improve breast cancer care and support patient needs.</p>\u0000 </section>\u0000 </div>","PeriodicalId":16795,"journal":{"name":"Journal of Pharmacy Practice and Research","volume":"53 4","pages":"177-185"},"PeriodicalIF":2.1,"publicationDate":"2023-06-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jppr.1871","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44650495","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Overview of factors influencing successful implementation of non-medical prescribing","authors":"Mariam Ghabour BPharm, MQM,&nbsp;Kyle John Wilby PharmD, PhD,&nbsp;Caroline J. Morris BPharm (Hons), MSc, PhD,&nbsp;Alesha J. Smith BSc, MSc, MBA, PhD","doi":"10.1002/jppr.1868","DOIUrl":"10.1002/jppr.1868","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Aim</h3>\u0000 \u0000 <p>This study sought to determine the factors influencing successful implementation of non-medical prescribing (NMP).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Data sources</h3>\u0000 \u0000 <p>EMBASE, Medline, CINAHL and reference lists were searched from January 2010 to November 2020.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Study Selection</h3>\u0000 \u0000 <p>Umbrella review and narrative synthesis of results were utilised. The retrieved reviews underwent title screening, abstract review, full-text screening and assessment for inclusion. To guarantee the precision of the search results, Participants, Intervention, Control, and Outcomes (PICO) elements were recorded for each study. Studies were included if they were systematic reviews, published in English, published from January 2010 to November 2020, and discussed barriers and/or facilitators to NMP implementation.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Of the 193 studies identified, eight were eligible for inclusion. Most of the reviews (62%) were published in 2017–2018. The majority of the reviews (62%) were focused on the United Kingdom. Three reviews discussed nurse prescribing, two reviews focused on pharmacist prescribing, and three reviews investigated NMP generally. Data were compiled into the Consolidated Framework for Implementation Research to evaluate the factors that influence the success or failure of NMP implementation.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Implementation of NMP is a complex process which requires fulfilment of all its elements. The success of NMP can be directly related to the extent of the whole system engagement and support, and available funding.</p>\u0000 </section>\u0000 </div>","PeriodicalId":16795,"journal":{"name":"Journal of Pharmacy Practice and Research","volume":"53 4","pages":"155-170"},"PeriodicalIF":2.1,"publicationDate":"2023-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jppr.1868","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47273155","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Self-reported neuropsychiatric adverse reactions in people receiving bictegravir combined with emtricitabine/tenofovir alafenamide","authors":"Aleksandra Trakilovic BPharm (Hons), GradCertPharmPrac,&nbsp;Linda Velta Graudins BPharm, DipHospPharm, DipClinPharmacoEpid, AdvPracPharm, FSHPA,&nbsp;Ar Kar Aung BMedSci, MBBS, FRACP, MPHTM,&nbsp;Jennifer Hoy MBBS, FRACP,&nbsp;Christopher K. Fairley MBBS, Ph. D, FRACP, FAFPHM, FACSHP,FAChSHM, FRCP, FAHMS,&nbsp;Ivette Aguirre MClinPharm, GradCertPharmPrac, BPharm, BAppSc(MedLabSc)","doi":"10.1002/jppr.1867","DOIUrl":"10.1002/jppr.1867","url":null,"abstract":"<p>The integrase-inhibitor bictegravir combination antiretroviral therapy (ART) Biktarvy became available in Australia in October 2018. Neuropsychiatric adverse drug reactions (ADRs) are associated with bictegravir and may affect persistence and adherence to treatment. The aim of this study was to describe the type and frequency of reported neuropsychiatric reactions in people dispensed Biktarvy. Ethics approval was obtained from Alfred Hospital Ethics Committee (Project No. 541/20). Data were collected from records of people dispensed Biktarvy between October 2018 and May 2020 and who subsequently had a new neuropsychiatric reaction reported to the organisation's ADR Review Committee. Data were sourced from ADR reports, medical and dispensing records, and included demographics, medical history, and concurrent medicines with known psychiatric adverse reactions. Data were analysed descriptively. Biktarvy was dispensed to 1265 patients. Twenty-two (1.7%, 95% confidence interval [CI] 1.0–2.5%) people reported 50 neuropsychiatric ADRs, including abnormal dreams (<i>n</i> = 13), sleep disorders (<i>n</i> = 5), and headaches (<i>n</i> = 5). The median time from initiation to reaction was 13 (interquartile range [IQR] 4–94) days. Eighteen patients discontinued Biktarvy (1.4%, 95% CI 0.85–2.24). There was no statistically significant difference in discontinuation of Biktarvy between people who did or did not have a pre-existing psychiatric diagnosis (p = 0.58). Concurrent medicines with known psychiatric adverse reactions were used by 10 people. A low rate of reported neuropsychiatric ADRs lead to discontinuation of Biktarvy, similar to rates in Biktarvy trials. This study adds to the post-marketing surveillance data of Biktarvy tolerance amongst people living with human immunodeficiency virus (HIV).</p>","PeriodicalId":16795,"journal":{"name":"Journal of Pharmacy Practice and Research","volume":"53 4","pages":"195-199"},"PeriodicalIF":2.1,"publicationDate":"2023-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jppr.1867","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49136977","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"What is the most cost-beneficial way to prepare micafungin for paediatric oncology patients?","authors":"Erica Li BPharm,&nbsp;Evonne Smith BPharm, GDipClinPharm","doi":"10.1002/jppr.1865","DOIUrl":"10.1002/jppr.1865","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>A recent change in local paediatric antifungal guidelines resulted in an increase in micafungin use. Micafungin is an expensive medicine costing AUD $80 per vial. The pharmacy aseptic production unit (APU) has the ability to compound doses to share vials of micafungin to minimise wastage.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Aim</h3>\u0000 \u0000 <p>To determine whether aseptically compounded and individually prepared doses of micafungin would be more cost-beneficial than nurses using whole vials prepared on the ward, and to determine which dose and numbers of doses would be most cost-beneficial to compound.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Method</h3>\u0000 \u0000 <p>A time and motion study of 20 patients determined how long it took for nurses and the pharmacy APU to prepare doses. An economic analysis of time, cost of labour, and consumables outlined the cost to make one to seven doses with doses ranging from 10 to 200 mg.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>On average, it took the pharmacy APU 42 min and nurses 9 min to prepare a single dose. Aseptically compounding one dose, whole vials (doses of 50 mg increments), and doses near whole vials had no cost-benefit. Aseptically compounding five doses or more had would result in a cost-benefit.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Depending on the dose required, cost savings could be obtained when the pharmacy APU prepared multiple doses, with a maximum saving of $350.10 for a 7-day course. Determining baseline costs of micafungin preparation is relevant if there are future requests to compound medicines as the data could be extrapolated and applied to the new request.</p>\u0000 </section>\u0000 </div>","PeriodicalId":16795,"journal":{"name":"Journal of Pharmacy Practice and Research","volume":"53 4","pages":"171-176"},"PeriodicalIF":2.1,"publicationDate":"2023-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42403238","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}